Shanghai-based biotech company Cataya, which specializes in synthetic biology, has reportedly raised RMB 250 million (USD 35 million) in a Series B financing round. The round was co-led by Hengxu Capital and Eight Roads Ventures, with additional investments from Hui Rong Technology Service and Bits x Bites.
Cataya’s DBTL Platform and Services
Founded in 2021, Cataya has established itself as a leader in synthetic biology by offering its DBTL (Design Build Test Learn) platform capabilities. These capabilities encompass a wide range of services, including data science, strain engineering, in vivo enzyme engineering, fermentation engineering, separation and purification, and large-scale production. The company’s comprehensive approach to synthetic biology is aimed at driving innovation across various industries.
Implications of the Financing Round
The successful Series B financing round will enable Cataya to further develop its DBTL platform and expand its service offerings. This funding is a testament to the growing interest and investment in synthetic biology, which has the potential to revolutionize fields such as pharmaceuticals, agriculture, and industrial chemicals.-Fineline Info & Tech
